RDRohit D'COsta

Rohit D'COsta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rohit D'COsta has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Perioperative Multidisciplinary Team Meetings: Illness Phases and Frailty in High‐Risk Surgical Candidates

    by Chuan‐Whei Lee, David Moore, Rohit D'COsta, Hannah Rotherham, Ned Douglas, Wen Kwang Lim, Jai Darvall

    Background: Perioperative multidisciplinary team meetings consider surgical benefit for high‐risk candidates. We explored how illness phases were associated with meeting recommendations. Methods: We conducted a retrospective cohort study of patients presented at our perioperative multidisciplinary team meetings between 2019 and 2022. Illness phases were defined using the modified surprise question: ‘even with surgery, would I be surprised if the patient dies in the next five years, twelve months, or one week?’ A ‘no’ response defined the ‘combined end‐of‐life’ phase, and ‘yes’ defined the ‘curative’ phase. The primary aim was to compare meeting recommendation to proceed to surgery between illness phases. Secondary aims included identifying predictors of meeting recommendation and whether patients underwent surgery. Results: There were 175 cases in 164 patients presented. Nineteen percent ( n = 33) were assessed as ‘curative’ phase and 81% ( n = 142) as ‘combined end‐of‐life’ phase. Surgery was recommended in 38% of cases ( n = 66), with no difference between curative versus combined end‐of‐life illness phases (33% vs. 39%, OR [95% CI] 0.79 [0.32–1.86], p = 0.69). However, multivariable logistic regression demonstrated that combined end‐of‐life phase cases were more likely to be recommended for surgery (OR [95% CI] 3.53 [1.22–10.25], p = 0.02). Patients with moderate to severe frailty were less likely to be either recommended for surgery (OR [95% CI] 0.15 [0.03–0.63], p = 0.005) or undergo surgery (OR [95% CI] 0.22 [0.04–0.88], p = 0.03). Conclusion: Illness phases were associated with meeting recommendations only on adjusted analysis, highlighting the need for further exploration. Frailty was the strongest predictor of both meeting recommendation and undergoing surgery.

  • Open Access

    Selective regulation of IFN-γ and IL-4 co-producing unconventional T cells by purinergic signaling

    by Calvin Xu, Andreas Obers, Minyi Qin, Alice Brandli, Joelyn Wong, Xin Huang, Allison Clatch, Aly Fayed, Graham Starkey, Rohit D’cOsta, et al.

    Unconventional T cells, including mucosal-associated invariant T (MAIT), natural killer T (NKT), and gamma-delta T (γδT) cells, comprise distinct T-bet+, IFN-γ+ and RORγt+, IL-17+ subsets which play differential roles in health and disease. NKT1 cells are susceptible to ARTC2-mediated P2X7 receptor (P2RX7) activation, but the effects on other unconventional T-cell types are unknown. Here, we show that MAIT, γδT, and NKT cells express P2RX7 and are sensitive to P2RX7-mediated cell death. Mouse peripheral T-bet+ MAIT1, γδT1, and NKT1 cells, especially in liver, co-express ARTC2 and P2RX7. These markers could be further upregulated upon exposure to retinoic acid. Blocking ARTC2 or inhibiting P2RX7 protected MAIT1, γδT1, and NKT1 cells from cell death, enhanced their survival in vivo, and increased the number of IFN-γ–secreting cells without affecting IL-17 production. Importantly, this revealed the existence of IFN-γ and IL-4 co-producing unconventional T-cell populations normally lost upon isolation due to ARTC2/P2RX7-induced death. Administering extracellular NAD in vivo activated this pathway, depleting P2RX7-sensitive unconventional T cells. Our study reveals ARTC2/P2RX7 as a common regulatory axis modulating the unconventional T-cell compartment, affecting the viability of IFN-γ– and IL-4–producing T cells, offering important insights to facilitate future studies into how these cells can be regulated in health and disease.


  • Open Access

    mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis

    by Angus T Stock, Sarah Parsons, Jacinta A Hansen, Damian B D’SIlva, Graham Starkey, Aly Fayed, Xin Yi Lim, Rohit D’COsta, Claire L Gordon, Ian P Wicks

    The accumulation of myofibroblasts within the intimal layer of inflamed blood vessels is a potentially catastrophic complication of vasculitis, which can lead to arterial stenosis and ischaemia. In this study, we have investigated how these luminal myofibroblasts develop during Kawasaki disease (KD), a paediatric vasculitis typically involving the coronary arteries. By performing lineage tracing studies in a murine model of KD, we reveal that luminal myofibroblasts develop independently of adventitial fibroblasts and endothelial cells, and instead derive from smooth muscle cells (SMCs). Notably, the emergence of SMC-derived luminal myofibroblasts—in both mice and patients with KD, Takayasu’s arteritis and Giant Cell arteritis—coincided with activation of the mechanistic target of rapamycin (mTOR) signalling pathway. Moreover, SMC-specific deletion of mTOR signalling, or pharmacological inhibition, abrogated the emergence of luminal myofibroblasts. Thus, mTOR is an intrinsic and essential regulator of luminal myofibroblast formation that is activated in vasculitis patients and therapeutically tractable. These findings provide molecular insight into the pathogenesis of coronary artery stenosis and identify mTOR as a therapeutic target in vasculitis.


  • Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles

    by Hyon-Xhi Tan, Jennifer A. Juno, Robyn Esterbauer, Hannah G. Kelly, Kathleen M. Wragg, Penny Konstandopoulos, Sheilajen Alcantara, Carolina Alvarado, Robert Jones, Graham Starkey, et al.

    Recent studies have established that memory B cells, largely thought to be circulatory in the blood, can take up long-term residency in inflamed tissues, analogous to widely described tissue-resident T cells. The dynamics of recruitment and retention of memory B cells to tissues and their immunological purpose remains unclear. Here, we characterized tissue-resident memory B cells (B RM ) that are stably maintained in the lungs of mice after pulmonary influenza infection. Influenza - specific B RM were localized within inducible bronchus-associated lymphoid tissues (iBALTs) and displayed transcriptional signatures distinct from classical memory B cells in the blood or spleen while showing partial overlap with memory B cells in lung-draining lymph nodes. We identified lung-resident markers, including elevated expression of CXCR3, CCR6, and CD69, on hemagglutinin (HA)– and nucleoprotein (NP)–specific lung B RM . We found that CCR6 facilitates increased recruitment and/or retention of B RM in lungs and differentiation into antibody-secreting cells upon recall. Although expression of CXCR3 and CCR6 was comparable in total and influenza-specific memory B cells isolated across tissues of human donors, CD69 expression was higher in memory B cells from lung and draining lymph nodes of human organ donors relative to splenic and PBMC-derived populations, indicating that mechanisms underpinning B RM localization may be evolutionarily conserved. Last, we demonstrate that human memory B cells in lungs are transcriptionally distinct to populations in lung-draining lymph nodes or PBMCs. These data suggest that B RM may constitute a discrete component of B cell immunity, positioned at the lung mucosa for rapid humoral response against respiratory viral infections.


  • A diverse fibroblastic stromal cell landscape in the spleen directs tissue homeostasis and immunity

    by Yannick O. Alexandre, Dominik Schienstock, Hyun Jae Lee, Luke C. Gandolfo, Cameron G. Williams, Sapna Devi, Bhupinder Pal, Joanna R. Groom, Wang Cao, Susan N. Christo, et al.

    A diverse fibroblastic stromal cell landscape in the spleen directs tissue homeostasis and immunity.


  • Open Access

    IMPLEMENTATION OF INCREASED VIRAL RISK DONOR WAITING LIST FOR PRE-CONSENTED WAITLISTED RECIPIENTS IN VICTORIA, AUSTRALIA

    by Nina Seng, Indra Gramnea, Fiona Hudson, Rohit D’costa, Leanne McEvoy, Joe Sasadeusz, Basu Gopal, Joshua Kausman, Rosemary Masterson, Kathy Paizis, et al.